Millendo Therapeutics Inc (MLND)


Stock Price Forecast

June 25, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Millendo Therapeutics Inc chart...

About the Company

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.

Exchange

NASDAQ CAPITAL MARKET

Website

www.millendo.com

$0M

Total Revenue

38

Employees

$16M

Market Capitalization

-0.62

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MLND News

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

12d ago, source:

We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. “With the Phase 2b data readout from our global IMPAHCT trial of ...

Peter W. Sonsini's Net Worth

4d ago, source: Benzinga.com

Who is Peter W. Sonsini? Peter W. Sonsini has an estimated net worth of $898 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian ...

Tempest and Millendo Announce Stockholder Approval of Merger

2mon ago, source: ADVFN

About Millendo Therapeutics, Inc. Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do ...

Joshua Makower's Net Worth

11d ago, source: Benzinga.com

Joshua Makower has an estimated net worth of $231 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian Therapeutics, Inc., Nkarta, Inc ...

Kintara Therapeutics Inc KTRA

14h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

CVKD Cadrenal Therapeutics, Inc.

4d ago, source: Seeking Alpha

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

23d ago, source: Yahoo Finance

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.

Viking Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

12d ago, source: Nasdaq

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...